Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma 1

Interventions

Cisplatin 29Magnetic Resonance Spectroscopy 16Specimen Handling 13Radiotherapy 12pembrolizumab 11Radiotherapy, Intensity-Modulated 11Cetuximab 11Surgical Procedures, Operative 9Paclitaxel 9Fluorouracil 9Docetaxel 9Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Radiation 6Carboplatin 6Taxes 5Biopsy 5toripalimab 4X-Rays 4Surveys and Questionnaires 4Fluorodeoxyglucose F18 4Chemoradiotherapy 4Celecoxib 4(225)Ac-DOTA-c(RGDyK) 4Immunohistochemistry 3Counseling 3130-nm albumin-bound paclitaxel 3motexafin gadolinium 2ipatasertib 2camrelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypopharyngeal Neoplasms × BAY 1895344 × Head & Neck × Clear all
NCT04576091 2024-12-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡